Ann: Invex Granted European Orphan Drug Designation for TBI, page-51

Was about to say something similar. Most drug therapeutics are a reformulation of another drug.

It would simply not make sense for a FDA / EMA to regard two different GLP-1 drugs with different active levels and treatment purposes as the same drug.

IXC has step-changed the value of its portfolio with this development - a portfolio that the market is still significantly under-valuing. And excitingly, pharma M&A is expected to rebound over the next 12-18 months, so IXC's announcement has somewhat fortuitous timing.